Casual blood glucose and subsequent cardiovascular disease and all-cause mortality among 159 731 participants in Cohort of Norway (CONOR).


Journal

BMJ open diabetes research & care
ISSN: 2052-4897
Titre abrégé: BMJ Open Diabetes Res Care
Pays: England
ID NLM: 101641391

Informations de publication

Date de publication:
02 2021
Historique:
received: 30 09 2020
revised: 20 12 2020
accepted: 07 02 2021
entrez: 24 2 2021
pubmed: 25 2 2021
medline: 1 7 2021
Statut: ppublish

Résumé

Our aim was to assess the association between casual blood glucose level and subsequent cardiovascular disease (CVD) and mortality among community-dwelling adults without a diagnosis of diabetes. In this community-based cohort study, 159 731 individuals with a measurement of casual blood glucose were followed from their participation date in Cohort of Norway (CONOR) (1994-2003) until a CVD episode, death or 31 December 2009. All analyses were done using Cox proportional hazard regression, and the results are reported as multivariable-adjusted HRs with 95% CI. Compared with those with normal glucose levels (<7.8 mmol/L), participants categorized as having borderline (7.8-11.0 mmol/L) levels showed an increased risk of a stroke (HR 1.29; 95% CI 1.12 to 2.49) and cardiovascular (HR 1.29; 95% CI 1.12 to 2.48), and all-cause (HR 1.27; 95% CI 1.16 to 1.38) mortality, while participants with high glucose levels (>11.0 mmol/L) had an even more increased risk. One mmol/L increase in glucose level was associated with an increased risk of all four endpoints among participants with borderline as well as within normal glucose levels. In analyses stratified by sex and age group, the CVD risk estimates tended to be higher in women than in men and in those <65 years of age but no significant interactions were found. An increase in casual blood glucose levels, even within the range of normal and borderline levels, was positively associated with increased risk of CVD and mortality among community-dwelling adults without a known diagnosis of diabetes.

Identifiants

pubmed: 33622686
pii: 9/1/e001928
doi: 10.1136/bmjdrc-2020-001928
pmc: PMC7907851
pii:
doi:

Substances chimiques

Blood Glucose 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Int J Epidemiol. 2014 Aug;43(4):1336-9
pubmed: 24706730
N Engl J Med. 2011 Mar 03;364(9):829-841
pubmed: 21366474
Arch Intern Med. 2004 Oct 25;164(19):2147-55
pubmed: 15505129
JAMA Cardiol. 2016 Oct 1;1(7):813-823
pubmed: 27437922
Diabetes Care. 2020 Jan;43(Suppl 1):S7-S13
pubmed: 31862744
Diabetes Care. 2019 Mar;42(3):416-426
pubmed: 30104301
Diabetes Care. 2013 Jul;36(7):1988-93
pubmed: 23404299
N Engl J Med. 2010 Mar 4;362(9):800-11
pubmed: 20200384
Diabetes Care. 1999 Feb;22(2):233-40
pubmed: 10333939
J Am Coll Cardiol. 2012 Jun 19;59(25):2356-65
pubmed: 22698489
BMJ Open. 2014 Jun 09;4(6):e005002
pubmed: 24913327
Int J Epidemiol. 2008 Jun;37(3):481-5
pubmed: 17984119
Diabetologia. 2014 Aug;57(8):1542-51
pubmed: 24859435
Diabetes Metab. 2017 Jun;43(3):261-264
pubmed: 27712966
Diabetes Care. 1993 Feb;16(2):434-44
pubmed: 8432214
N Engl J Med. 2015 Oct 29;373(18):1720-32
pubmed: 26510021
Diabetologia. 2008 Apr;51(4):575-82
pubmed: 18197396
Diabetes Care. 2002 Oct;25(10):1790-4
pubmed: 12351479
Curr Med Res Opin. 2011 Nov;27(11):2155-63
pubmed: 21973198
Diabetes Care. 1998 Jul;21(7):1167-72
pubmed: 9653614
Diabetologia. 2013 Feb;56(2):284-93
pubmed: 23093136
Am J Cardiol. 2014 Jun 1;113(11):1777-81
pubmed: 24746031
Circulation. 2015 Jan 27;131(4):e29-322
pubmed: 25520374
Arch Intern Med. 2002 Aug 12-26;162(15):1737-45
pubmed: 12153377
BMC Public Health. 2012 Sep 19;12:806
pubmed: 22992417
Diabetes Care. 2010 Jan;33 Suppl 1:S62-9
pubmed: 20042775
Lancet. 2014 Jun 7;383(9933):1973-80
pubmed: 24613026
Prev Med. 2012 Dec;55(6):603-7
pubmed: 23010435
BMJ. 2000 Aug 12;321(7258):405-12
pubmed: 10938048
Lancet. 2010 Jun 26;375(9733):2215-22
pubmed: 20609967

Auteurs

Hilde Kristin Refvik Riise (HKR)

Department of Health and Caring Sciences, Western Norway University of Applied Sciences, Bergen, Vestlandet, Norway hkrr@hvl.no.

Jannicke Igland (J)

Department of Global Public Health and Primary Care, University of Bergen, Bergen, Vestlandet, Norway.

Gerhard Sulo (G)

Centre for Disease Burden, Division of Mental and Physical Health, Norwegian Institute of Public Health, Bergen, Vestlandet, Norway.
Oral Health Centre of Expertise in Western Norway, University of Bergen, Bergen, Vestlandet, Norway.

Marit Graue (M)

Department of Health and Caring Sciences, Western Norway University of Applied Sciences, Bergen, Vestlandet, Norway.

Johannes Haltbakk (J)

Department of Health and Caring Sciences, Western Norway University of Applied Sciences, Bergen, Vestlandet, Norway.

Grethe Seppola Tell (GS)

Department of Global Public Health and Primary Care, University of Bergen, Bergen, Vestlandet, Norway.
Division of Mental and Physical Health, Norwegian Institute of Public Health, Bergen, Vestlandet, Norway.

Marjolein Memelink Iversen (MM)

Department of Health and Caring Sciences, Western Norway University of Applied Sciences, Bergen, Vestlandet, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH